Product Information
TRI-LEGEST FE-28 DAY TABLET is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $0.7459 per EA under NDC 00555903270. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Oct 26, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00555903270
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA076105FDA Approved
10/26/2007
TE Code
AB
On Market Since
10/26/2007
Price Statistics
The NADAC for TRI-LEGEST FE-28 DAY TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 38.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.7459 per EA |
|---|---|
| All-time high | $1.6913 (Mar 13, 2019) |
| All-time low | $0.5989 (Jul 17, 2024) |
| 52-week high | $1.1890 |
| 52-week low | $0.7459 |
| Median price | $1.1838 |
| Average price | $1.1664 |
| Largest weekly change | +48.5% (Jan 23, 2019) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Norethindrone Acetate and Ethinyl Estradiol market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Norethindrone Acetate and Ethinyl Estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRI-LEGEST FE-28 DAY TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRI-LEGEST FE-28 DAY TABLET, manufactured by Teva Pharmaceuticals USA Inc., is $0.7459 per EA (NDC 00555903270), effective Sep 30, 2026.
How has the price of TRI-LEGEST FE-28 DAY TABLET changed over time?
Over the history we have for it, the NADAC for TRI-LEGEST FE-28 DAY TABLET has declined 38.9%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TRI-LEGEST FE-28 DAY TABLET?
Since Nov 28, 2013, the NADAC for TRI-LEGEST FE-28 DAY TABLET has ranged from a low of $0.5989 (Jul 17, 2024) to a high of $1.6913 (Mar 13, 2019), with a median of $1.1838 per EA.
Are there cheaper alternatives to TRI-LEGEST FE-28 DAY TABLET?
No other NADAC-published product currently shares the active ingredient and strength of TRI-LEGEST FE-28 DAY TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures TRI-LEGEST FE-28 DAY TABLET?
TRI-LEGEST FE-28 DAY TABLET (NDC 00555903270) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.